Osaic Holdings
SYRE icon

Osaic Holdings’s Spyre Therapeutics SYRE Stock Holding History

Osaic Holdings’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
18,146
+17,648
+3,544% +$1.29M ﹤0.01% 2519
2026
Q1 		$25.1K Buy
498
+131
+36% +$4.94K ﹤0.01% 5713
2025
Q4 		$12K Buy
367
+53
+17% +$1.39K ﹤0.01% 6222
2025
Q3 		$5.17K Buy
314
+14
+5% +$228 ﹤0.01% 6731
2025
Q2 		$4.49K Buy
300
+62
+26% +$917 ﹤0.01% 6602
2025
Q1 		$3.84K Buy
238
+133
+127% +$2.77K ﹤0.01% 6309
2024
Q4 		$2.44K Buy
105
+22
+27% +$645 ﹤0.01% 6529
2024
Q3 		$2.44K Hold
83
– – ﹤0.01% 6536
2024
Q2 		$1.95K Hold
83
– – ﹤0.01% 6603
2024
Q1 		$3.15K Sell
83
-200
-71% -$5.79K ﹤0.01% 6298
2023
Q4 		$6.09K Hold
283
– – ﹤0.01% 6078
2023
Q3 		$3.47K Buy
283
+83
+42% +$1.1K ﹤0.01% 6423
2023
Q2 		$2.25K Buy
+200
New +$948 ﹤0.01% 6624
2022
Q3 		– Sell
-19
Closed – – 7500
2022
Q2 		$0 Buy
+19
New +$666 ﹤0.01% 7586
2020
Q4 		– Sell
-31
Closed -$6K – 6556
2020
Q3 		$6K Hold
31
– – ﹤0.01% 5521
2020
Q2 		$7K Hold
31
– – ﹤0.01% 5339
2020
Q1 		$4K Buy
+31
New +$5.27K ﹤0.01% 5462

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Osaic Holdings's SYRE Position: Q2 2026 in Review

Osaic Holdings increased its Spyre Therapeutics (SYRE) stake by 3,544% in Q2 2026, buying an estimated $1.29M and bringing the position to 18,146 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2519.

Osaic Holdings first reported a position in SYRE in Q1 2020 and has held it in 17 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Osaic Holdings held 18,146 shares of Spyre Therapeutics worth $1.61M as of Q2 2026.
  • Osaic Holdings bought 17,648 Spyre Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Spyre Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #2519 holding.
  • Osaic Holdings first reported a position in Spyre Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.